Publication date: Apr 20, 2019
AIM at Melanoma Opens First Melanoma Tissue Bank in the U. S Apr 20, 2019 (8 hours ago) | PRN SAN RAFAEL, Calif: AIM at Melanoma announces the grand opening of the first branch of the International Melanoma Tissue Bank Consortium (IMTBC) at the University of Pittsburgh Medical Center (UPMC), Hillman Cancer Center.
The IMTBC is a global first because of the following combination of factors It’s a consortium-the six institutions are sharing data and tissue samples with each other It’s collaborative-tissue samples and data will be available for researchers around the world to apply to study The tissue will be fresh frozen-RNA is preserved, unlike in the standard formalin fixed, paraffin embedded process The tumors are primary-not metastasized There will be a critical mass-a goal of 500 in the first two years, and continued collection thereafter Full annotation will accompany each tissue-patient data, including full medical history (depersonalized) will be available for study along with the tissue Samples will accompany each tissue-blood and urine samples will be collected for each patient The primary tumor is the holy grail of resources for melanoma researchers, says John M. Kirkwood, MD, Usher Professor of Medicine, Dermatology and Translational Science and co-Leader, Melanoma and Skin Cancer Program, UPMC Hillman Cancer Center.
Fifteen years ago, many researchers told me that a collaborative fresh-frozen primary tissue bank would propel research, but they also told me it would be impossible to accomplish, says Val Guild, the Founder President of AIM at Melanoma, who lost her 26 year old daughter, Charlie, to the disease in 2003.
- AIM at Melanoma Opens First Melanoma Tissue Bank in the U.S.
- Melanoma-induced reprogramming of Schwann cell signaling aids tumor growth.